Sign in
EH

Envista Holdings Corp (NVST)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 was “in line with expectations”: sales $652.9M (+1.1% y/y), core sales +2.0%, Adjusted EBITDA $91.0M (13.9% margin) and Adjusted EPS $0.24; operating cash flow $132.4M and free cash flow $123.9M (+30% and +24% y/y) .
  • Implants returned to growth (Nobel premium and Challenger value) and Spark aligners continued share gains with sequential gross margin improvement; Diagnostics remained soft; China orthodontics saw 50% decline in brackets/wires ahead of VBP implementation .
  • FY2025 guidance introduced: core sales +1% to +3%, ~14% Adjusted EBITDA margin, Adjusted EPS $0.95–$1.05; assumptions include ~2% FX revenue headwind, 37% ETR, tariff impacts excluded for now, and a tailwind from 2024 Spark revenue deferrals mostly in 2H25; $20M gross restructuring savings and a new $250M share repurchase authorization through 2026 .
  • Key stock narrative catalysts: execution on Spark margin/2H25 profitability, durability of implants recovery (esp. North America Nobel), Diagnostics stabilization on lower rates, and clarity on China orthodontics VBP cadence .

What Went Well and What Went Wrong

  • What Went Well

    • “We delivered core growth of 2% and an adjusted EBITDA margin around 14%,” with improved performance in implants (Nobel and Challenger) and continued share gains and gross margin improvement in Spark .
    • Consumables posted strong growth on easier comps; segment Adjusted operating margin in Equipment & Consumables rose to 25.2% on higher consumables volumes and FX transaction gains .
    • Cash generation remained strong: Q4 operating cash flow $132.4M and free cash flow $123.9M; FY24 FCF $302.8M (+35% y/y) .

  • What Went Wrong

    • Diagnostics contracted again (notably China and other markets), with North America also down mid-single digits after prior growth streak; IOS also contracted .
    • China orthodontics brackets/wires down ~50% in Q4 due to VBP preparations; management expects a slow 1H25 and improvement post-implementation .
    • Adjusted EBITDA margin (13.9%) declined y/y due to Spark deferral headwind, growth investments (notably Nobel), and incentive comp; Adjusted EPS fell to $0.24 from $0.29 y/y .

Financial Results

Overall financials (oldest → newest)

MetricQ4 2023Q3 2024Q4 2024
Revenue ($M)$645.6 $601.0 $652.9
GAAP Diluted EPS$(1.27) $0.05 $0.01
Adjusted Diluted EPS$0.29 $0.12 $0.24
Gross Margin % (GAAP)52.0% 52.8% 57.1%
Adjusted Gross Margin %52.4% 52.8% 57.2%
Adjusted EBITDA ($M)$100.5 $54.9 $91.0
Adjusted EBITDA Margin %15.6% 9.1% 13.9%
Operating Cash Flow ($M)$102.0 $70.7 $132.4
Free Cash Flow ($M)$99.9 $63.3 $123.9

Segment performance (sales and adjusted margins; oldest → newest)

SegmentQ4 2023 Sales ($M)Q4 2023 Adj Op Margin %Q3 2024 Sales ($M)Q3 2024 Adj Op Margin %Q4 2024 Sales ($M)Q4 2024 Adj Op Margin %
Specialty Products & Technologies415.9 15.4% 381.7 7.0% 410.9 11.5%
Equipment & Consumables229.7 19.5% 219.3 20.0% 242.0 25.2%

KPIs (Quarter)

KPI (Q4 2024)Value
Core Sales Growth (Consolidated)+2.0% y/y
Adjusted EBITDA Margin13.9%
Operating Cash Flow$132.4M
Free Cash Flow$123.9M

Notes: Spark revenue deferral headwind ~$(7)M in Q4 (full-year 2024 net deferral headwind ~$45M), turning to tailwind in 2025 (largest in Q3) .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Core Sales GrowthFY2025—+1% to +3% New
Adjusted EBITDA MarginFY2025—~14% New
Adjusted EPSFY2025—$0.95–$1.05 New
Effective Tax RateFY2025—~37% New detail
FX AssumptionFY2025—Flat to YE’24; EUR/USD 1.04; ~2% revenue headwind New
TariffsFY2025—Not included given uncertainty New
Spark DeferralsFY2025—Modest 1Q headwind; ~2/3 of FY24 deferral turns to tailwind in 2H (largest in Q3) New
Restructuring Savings (gross)Run-rate—~$20M annualized New
Share Repurchases2025–2026—Up to $250M authorized through 2026 New

Earnings Call Themes & Trends

TopicQ2 2024 (Q-2)Q3 2024 (Q-1)Q4 2024 (Current)Trend
Spark alignersIncreased deferral; active doctors +20% ytd; double-digit unit cost reduction; building global mfg footprint Spark grew ex-deferral; cases/doctors up double digits; deferral impact $27M in Q3; heavy P&L fall-through Continued share gains, sequential gross margin improvement; 2H25 operating profit expected; 2024 deferral headwind ~$45M, tailwind in 2H25 Improving unit economics; near-term deferral drag flips to tailwind
ImplantsValue up modestly; premium underperforming; stepped-up investments (~$6M/qtr) Gap to market narrowing; value growth; premium improving; NA still lagging Returned to growth in Q4 for both Nobel and Challenger; full-arch volumes a positive signal Momentum building, esp. in NA Nobel
DiagnosticsDown high single digits; ex-NA weakness; exited lower-priority geos Soft; NA up; China/Europe sharp declines Contracted; NA down mid-single digits after 3Q growth streak; IOS contracted Remains pressured; watching rates/financing sensitivity
ChinaEM volatility; China declined low single digits in Q2 China diag weakness; inventory normalization ongoing Ortho brackets/wires down ~50% y/y on VBP prep; 1H25 slow, improve later; Diagnostics weak VBP trough near-term; staged recovery expected
Consumables & channelNA channel inventory drawdown pressuring sell-in Channel inventory stable q/q; sell-out flat to low single digits Strong Q4 growth on easy comps; underlying sell-out flat; inventory stable Normalizing; comp tailwinds fade into 2025
FX/interest/macroHigher rates pressuring Diagnostics; soft but stable market Market soft/stable; price contribution; EBITDA bridge FX losses FX ~2% 2025 revenue headwind; margin headwind; macro/tariff uncertainty Macro still a headwind

Management Commentary

  • “Results for Q4 were again in line with our expectations. We delivered core growth of 2% and an adjusted EBITDA margin around 14%... continued improvement in our implants business... another quarter of share gains and gross margin improvement in Spark” — Paul Keel, CEO .
  • “Our guidance... core growth of 1% to 3% and adjusted EBITDA margin of approximately 14%... adding EPS of $0.95 to $1.05” — Paul Keel .
  • “We expect a gross benefit of $20 million in annualized savings from our recent restructuring... [and] our Board... authorized up to $250 million in share repurchases between now and the end of 2026” — Paul Keel; Eric Hammes, CFO .
  • “Diagnostics... declined high single digits... China, in particular, continued to experience sharp declines... North America also declined mid-single digits” — Eric Hammes .
  • “Spark is about a $250 million business... every point of margin improvement gives you ~10 bps at the Envista level” — Eric Hammes .

Q&A Highlights

  • Upside/levers vs guide: Potential outperformance from Spark share/margins, implants improvement, Diagnostics if capital demand recovers faster; margin opportunities from Spark profitability and G&A .
  • Implants trajectory: Continued momentum expected; investments in leadership, go-to-market, clinical, and innovation underpin confidence; not assuming material market acceleration .
  • Diagnostics outlook: Expect flat to low-single-digit growth in 2025; modest improvement from mix/exits; macro-dependent .
  • Spark profitability: Business ~$250M; 10 bps of corporate margin per 1 pt Spark margin; profitability targeted 2H25; cost-down/automation the main driver .
  • Margin cadence: Lower in 1H and higher in 2H (Spark tailwind timing, China VBP cadence); full-year ~14% .
  • Tariffs readiness: No tariff impact in guide; local-for-local diversified manufacturing footprint provides flexibility .

Estimates Context

  • Wall Street consensus (S&P Global) for Q4 2024 and FY estimates was unavailable at time of analysis due to S&P Global request limits; therefore, we cannot provide “vs. consensus” beats/misses for revenue or EPS at this time. Values retrieved from S&P Global were unavailable due to request limit.

Key Takeaways for Investors

  • Execution turning: Q4 met expectations with resumed growth, improved gross margins, strong FCF, and tangible progress in implants and Spark; medium-term hinges on sustaining implants momentum and delivering Spark 2H25 profitability .
  • 2025 set-up conservative: Guide assumes flat market, FX headwind, and excludes tariffs; Spark deferral flips to tailwind largely in 2H with largest impact in Q3, implying back-half weighted growth and margins .
  • Cash returns begin: $250M buyback authorization over two years signals confidence in cash generation; $20M restructuring savings support margin stability while growth investments continue .
  • Watch Diagnostics inflection: Lower rates could improve capital demand; near-term still soft—any acceleration would be an upside surprise to guide .
  • China risk manageable but near-term drag: Ortho VBP creates 1H25 headwind; improvement expected post-implementation; implants VBP experience provides a template .
  • Operating rigor: EBS-driven productivity, price capture, and working capital discipline underpin FCF resiliency, providing buffer amid macro uncertainty .
  • Trading bias: Near-term choppy (1H) with clearer catalysts into 2H (Spark tailwind, China lap, CMD targets), suggesting better risk/reward on pullbacks as execution evidence builds .

Appendix: Additional Q4 Materials and Prior Quarters

  • Q4 2024 press release (8-K Exhibit 99.1): Financial statements, segment data, non-GAAP reconciliations .
  • Envista Q4 2024 results press release (standalone): summary, guidance, reconciliations .
  • Q3 2024 press release and 8-K: trend context (core -5.3%, Adj EBITDA 9.1%); segment and non-GAAP reconciliations .
  • Q2 2024 press release and 8-K: initial deferral/channel impacts, impairment, reinstated 2024 guidance .